Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.

ABSTRACT:

Importance

Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the efficacy and safety of ICI rechallenge in mRCC is unknown.

Objective

To evaluate the safety and efficacy of ICI rechallenge in patients with mRCC.

Design, setting, and participants

This multicenter, retrospective cohort study included consecutive patients with mRCC from 9 institutions in the US who received at least 2 separate lines of ICI (ICI-1, ICI-2) between January 2012 and December 2019.

Exposure

Receipt of an ICI (anticytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1, or anti-programmed cell death ligand 1), alone or in combination with other therapies, in at least 2 separate lines of

SUBMITTER: Ravi P 

PROVIDER: S-EPMC7260689 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature